systemic lupus erythematosus
Conditions
Interventions
Belimumab + standard therapy group 1:Belimumab(5mg/kg.m)+ standard therapy
Belimumab + standard therapy group 2:Belimumab(10mg/kg.m)+standard therapy
Belimumab + standard of care group 3:Belimumab(10mg/kg.2m)+standard of care group
Sponsors
Affiliated Hospital of Guilin Medical College
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Those who voluntarily sign the informed consent form, are able to comply with the plan and have the ability to carry out relevant procedures; 2. Age 16 to 65 years old, both men and women, the gender ratio is not limited; 3. Patients diagnosed with active SLE who have used belimumab for 1 course and achieved SRI-4 response. (At least 4 of the 11 criteria for SLE revised by the American College of Rheumatology in 1997 were met at the time of diagnosis)
Exclusion criteria
Exclusion criteria: Due to other circumstances, the investigator believes that it is not suitable to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The time of the first flare; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lupus Comprehensive Evaluation Index BICLA Score;Adverse events;Lupus Comprehensive Evaluation Index SRI-4 Score; | — |
Countries
China
Contacts
Public ContactMo Hanyou
Affiliated Hospital of Guilin Medical College
Outcome results
None listed